{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:53:13Z","timestamp":1787964793390,"version":"build-2784847793"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ygyno.2018.01.009","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T21:27:26Z","timestamp":1517606846000},"page":"609-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Cervical cancer \u2013 State of the science: From angiogenesis blockade to checkpoint inhibition"],"prefix":"10.1016","volume":"148","author":[{"given":"Lindsey E.","family":"Minion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8417-7000","authenticated-orcid":false,"given":"Krishnansu S.","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.01.009_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin"},{"issue":"10","key":"10.1016\/j.ygyno.2018.01.009_bb0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1089\/jwh.2011.3385","article-title":"Cervical cancer trends in the United States: a 35-year population-based analysis","volume":"21","author":"Adegoke","year":"2012","journal-title":"J. Women's Health (Larchmt)"},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.009_bb0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0020","author":"Center for Disease Control and Prevention"},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.009_bb0025","article-title":"Smoking behavior in women with locally advanced cervical carcinoma: a Gynecologic Oncology Group study","volume":"202","author":"Waggnor","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"9","key":"10.1016\/j.ygyno.2018.01.009_bb0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.ygyno.2018.01.009_bb0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.11141","article-title":"Meta-analysis of social inequality and the risk of cervical cancer","volume":"105","author":"Parikh","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2018.01.009_bb0040","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1985.3.8.1079","article-title":"Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology study","volume":"3","author":"Bonomi","year":"1985","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.009_bb0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0090-8258(89)80033-2","article-title":"A randomized comparison of a rapid versus prolonged (24\u202fhr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology study","volume":"32","author":"Thigpen","year":"1989","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2018.01.009_bb0050","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.1989.7.10.1462","article-title":"A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study","volume":"7","author":"McGuire","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.009_bb0055","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1997.15.1.165","article-title":"Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Groups Study","volume":"15","author":"Omaura","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2018.01.009_bb0060","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","article-title":"Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"22","author":"Moore","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2018.01.009_bb0065","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Long","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"10.1016\/j.ygyno.2018.01.009_bb0070","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.009_bb0075","first-page":"108","article-title":"The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma","volume":"8","author":"Tewari","year":"2010","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s002800100327","article-title":"Synergistic interaction between topotecan and microtubule-interfering agents","volume":"48","author":"Bahadori","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0085","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ygyno.2003.11.019","article-title":"Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma","volume":"92","author":"Tieresten","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40661-015-0015-0","article-title":"Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future","volume":"2","author":"Rodriguez-Freixinos","year":"2015","journal-title":"Gynecol. Oncol. Res. Pract."},{"issue":"4","key":"10.1016\/j.ygyno.2018.01.009_bb0095","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J. Clin. Pathol."},{"issue":"40","key":"10.1016\/j.ygyno.2018.01.009_bb0100","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1038\/sj.onc.1203817","article-title":"Oncogenes and tumor angiogenesis: the HPV-16 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner","volume":"19","author":"Lopez-Ocejo","year":"2000","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ygyno.2018.01.009_bb0105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0002-9378(98)80018-5","article-title":"Tumor angiogenesis in stage IB cervical cancer: correlation of microvessel density with survival","volume":"178","author":"Obermair","year":"1998","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.009_bb0110","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ygyno.2008.11.013","article-title":"Markers of angiogenesis in high-risk, early stage cervical cancer: a gynecologic group study","volume":"112","author":"Randall","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2018.01.009_bb0115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJM199804023381412","article-title":"Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470","volume":"338","author":"Kudelka","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0120","first-page":"1501","article-title":"A phase I study of TNP-470 administered to patiens with advanced squamous cell cancer of the cervix","volume":"3","author":"Kudelka","year":"1997","journal-title":"Clin. Cancer Rex."},{"issue":"7","key":"10.1016\/j.ygyno.2018.01.009_bb0125","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.ygyno.2018.01.009_bb0130","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0135","author":"National Cancer Institute"},{"issue":"8","key":"10.1016\/j.ygyno.2018.01.009_bb0140","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.009_bb0145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomized, phase 3 trial (NRG Oncology\u2013Gynecologic Oncology Group protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0150","article-title":"Bevacizumab for advanced cervical cancerL final overall survival and adverse event analysis of a randomised, controlled, open-label, phase III trial (Gynecologic Oncology Group 240)","volume":"27","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.009_bb0155","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2009.09.006","article-title":"Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology group study","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2018.01.009_bb0160","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-15-1346","article-title":"Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with\/without bevacizumab: NRG Oncology\/GOG study","volume":"21","author":"Tewari","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2018.01.009_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2015.01.358","article-title":"Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Waggoner","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2018.01.009_bb0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2015.01.026","article-title":"Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer. An NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Tewari","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"s4","key":"10.1016\/j.ygyno.2018.01.009_bb0175","article-title":"Fistulae in women treated with chemotherapy +\/\u2212 bevacizumab for persistent, recurrent or metastatic cervical cancer in GOG-240: an NRG Oncology\/Gynecologic Oncology Group study","volume":"24","author":"Willmott","year":"2014","journal-title":"IGCS"},{"key":"10.1016\/j.ygyno.2018.01.009_bb0180","article-title":"Prognostic impact of histology in recurrent and metastatic cervical carcinoma: an NRG Oncology\/Gynecologic Oncology Group study","author":"Seamon","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2018.01.009_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ygyno.2015.01.064","article-title":"Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Eskander","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"s3","key":"10.1016\/j.ygyno.2018.01.009_bb0190","article-title":"Patient-reported outcomes and toxicity at discontinuation of the therapy in advanced or persistent cervical cancer: an analysis of GOG protocol 240","volume":"26","author":"Chase","year":"2016","journal-title":"IGCS"},{"key":"10.1016\/j.ygyno.2018.01.009_bb0195","doi-asserted-by":"crossref","first-page":"395","DOI":"10.6004\/jnccn.2015.0055","article-title":"Cervical cancer, version 2.2015","volume":"13","author":"Koh","year":"2015","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.ygyno.2018.01.009_bb0200","first-page":"39","article-title":"A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer","volume":"47","author":"Sugiyama","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.01.009_bb0205","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2015.02.027","article-title":"A markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advance cervical cancer","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"19","key":"10.1016\/j.ygyno.2018.01.009_bb0210","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III Trial JGOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.ygyno.2018.01.009_bb0215","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","article-title":"Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CiRCCa): a randomized, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Symonds","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7488","key":"10.1016\/j.ygyno.2018.01.009_bb0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature12881","article-title":"Landscape of genomic alterations in cervical carcinomas","volume":"506","author":"Ojesina","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2018.01.009_bb0225","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3389\/fimmu.2017.00689","article-title":"Cervical cancer neoantigen landscape and immune activity is associated with human papillomavirus master regulators","volume":"8","author":"Qin","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2018.01.009_bb0235","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3776","article-title":"Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma","author":"Lheureux","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0240","author":"U.S. National Library of Medicine"},{"issue":"9895","key":"10.1016\/j.ygyno.2018.01.009_bb0245","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human papillomavirus and cervical cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2018.01.009_bb0250","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/imm.12101","article-title":"Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia","volume":"139","author":"Yang","year":"2013","journal-title":"Immunol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0255","author":"U.S. Food and Drug Administration"},{"issue":"7","key":"10.1016\/j.ygyno.2018.01.009_bb0260","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicenter, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.ygyno.2018.01.009_bb0265","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Baumi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0270","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/annonc\/mdx440.040","article-title":"Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous carcinoma (R\/M HNSCC): phase 3 KEYNOTE-040","volume":"28","author":"Cohen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.ygyno.2018.01.009_bb0275","article-title":"Treatment Beyond Progression With Nivolumab in Patients With Recurrent or Metastatic (R\/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Phase 3 Checkmate 141 Study: A Biomarker Analysis and Updated Clinical Outcomes","volume":"28","author":"Haddad","year":"2017","journal-title":"Annals. Oncol."},{"issue":"Suppl 5","key":"10.1016\/j.ygyno.2018.01.009_bb0280","article-title":"Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer","volume":"28","author":"Glisson","year":"2017","journal-title":"Annals. Oncol."},{"issue":"suppl_5","key":"10.1016\/j.ygyno.2018.01.009_bb0285","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx374","article-title":"Durvalumab for recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study","volume":"28","author":"Zandberg","year":"2017","journal-title":"Ann. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2018.01.009_bb0290","doi-asserted-by":"crossref","first-page":"P152","DOI":"10.1186\/2051-1426-3-S2-P152","article-title":"Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab\u202f+\u202ftremelimumab, in patients with recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR","volume":"3","author":"Gilbert","year":"2015","journal-title":"J. Immunother. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2018.01.009_bb0295","doi-asserted-by":"crossref","first-page":"P150","DOI":"10.1186\/2051-1426-3-S2-P150","article-title":"Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab\u202f+\u202ftremelimumab, versus standard of care (SoC), in recurrent or metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN): eagle","volume":"3","author":"Ferris","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2018.01.009_bb0300","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012","volume":"68","author":"Karia","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0305","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational landscape of aggressive cutaneous squamous cell carcinoma","volume":"15","author":"Pickering","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"15 suppl","key":"10.1016\/j.ygyno.2018.01.009_bb0310","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2017.35.15_suppl.9503","article-title":"REGN2810: a fully human anti-PD-1 monoclonal antibody for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) - initially safety and efficacy from expansion cohorts (ECs) of phase I study","volume":"35","author":"Papadopoulos","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15 suppl","key":"10.1016\/j.ygyno.2018.01.009_bb0315","doi-asserted-by":"crossref","first-page":"5504","DOI":"10.1200\/JCO.2017.35.15_suppl.5504","article-title":"An Open-label, Multicohort, Phase I\/II Study of Nivolumab in Patients With Virus-associated Tumors (CheckMate 358): Efficacy and Safety in Recurrent or Metastatic (R\/M) Cervical, Vaginal, and Vulvar Cancers","volume":"35","author":"Hollebecque","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0320","author":"U.S. National Library of Medicine"},{"key":"10.1016\/j.ygyno.2018.01.009_bb0325","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"35 suppl","key":"10.1016\/j.ygyno.2018.01.009_bb0330","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1200\/JCO.2017.35.15_suppl.5514","article-title":"Pembrolizumab for Previously Treated Advanced Cervical Squamous Cell Cancer: Preliminary Results From the Phase 2 KEYNOTE-158 Study","author":"Schellens","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.3024","article-title":"A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionaed radiotherapy (hfRT)","volume":"34","author":"Papadopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0340","author":"U.S. National Library of Medicine"},{"issue":"23","key":"10.1016\/j.ygyno.2018.01.009_bb0345","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0350","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9001","article-title":"Impact of atezolizumab (atezo) treatment beyond progression (TBP) in advanced NSCLC: results from the randomized phase III OAK study","volume":"35","author":"Gandara","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0355","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-14-1913","article-title":"Chemotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer","volume":"74","author":"Parikh","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0360","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","article-title":"Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial","volume":"16","author":"Golden","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0365","first-page":"311","article-title":"Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy","volume":"8","author":"Kumar","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ygyno.2018.01.009_bb0370","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818300416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818300416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T02:26:57Z","timestamp":1570674417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818300416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0090825818300416"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.009","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cervical cancer \u2013 State of the science: From angiogenesis blockade to checkpoint inhibition","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}